3'-Selenobisalanine" No Further a Mystery
All enrolled sufferers who gained not less than one particular dose of zosuquidar or placebo through induction were being monitored to the incidence of adverse occasions (439 clients, 219 on zosuquidar and 210 on placebo). The most typical adverse activities had been related to the period of prolonged and considerable myelosuppression as is anticip